LeonaBio

LeonaBio AAQS

The The AAQS of LeonaBio (LONA) as of Oct 19, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

LeonaBio has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock LeonaBio in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The LeonaBio AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
1.00 USD
Jan 1, 2019
1.00 USD
Jan 1, 2020
1.00 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
1.00 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
Jan 1, 2025
1.00 USD
The LeonaBio AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? LeonaBio Inc, trading under the ticker LONA with ISIN US04746L2034, is a U.S.-based company headquartered in Bothell, Washington. Operating within the Health Care sector, specifically in the Pharmaceuticals industry, the company has a workforce of 20 employees. LeonaBio Inc. completed its initial public offering (IPO) on September 18, 2020. The company's website is https://www.athira.com/. It is important to note that the provided source description refers to Athira Pharma, Inc., which appears to be a different entity from LeonaBio Inc. The source description mentions a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, with a pipeline built from an ATH platform. However, these details are not confirmed as part of LeonaBio Inc. and should not be attributed to it. The company's actual business focus, product pipeline, or technological platforms are not specified in the provided information. LeonaBio Inc. is a publicly traded company with a small team, operating in the pharmaceutical space, but specific details about its products, research, or development activities are not included in the facts provided. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

The AAQS of LeonaBio is 1 in 2025.

On Eulerpool you can find the complete historical development of The AAQS LeonaBio since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — LeonaBio

All Key Metrics — LeonaBio